Wagner M. Zago
About Wagner M. Zago
Wagner M. Zago Chief Scientific Officer
Wagner M. Zago serves as the Chief Scientific Officer. In his role, he is responsible for overseeing scientific research and development for the company. He provides strategic direction for the scientific team and ensures that research initiatives align with the company’s goals and objectives. His expertise and leadership are critical in advancing the company's pipeline of therapeutic candidates.
Wagner M. Zago Education and Expertise
Wagner M. Zago has demonstrated extensive expertise in the field of amyloidosis research and monoclonal antibody development. His research contributions include studies on organ response in patients with AL amyloidosis and developing therapeutics targeting amyloid deposits. Zago’s work has been instrumental in advancing scientific understanding and potential treatments for amyloidosis and Parkinson's disease.
Wagner M. Zago Contributions to Amyloidosis Research
Wagner M. Zago has significantly contributed to amyloidosis research. He co-authored a publication on the VITAL trial for birtamimab in light chain amyloidosis. Zago also participated in the development of NEOD001, a monoclonal antibody aimed at treating AL amyloidosis, and contributed to the creation of 2A4, which promotes the clearance of amyloid deposits by phagocytosis. His work in this area has been pivotal in developing potential treatments for amyloid-related conditions.
Wagner M. Zago Publications on Monoclonal Antibodies
Wagner M. Zago has co-authored several important publications on monoclonal antibodies. Notably, he contributed to a study on the safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti–α-synuclein monoclonal antibody, in patients with Parkinson’s disease. Zago also co-authored research on a monoclonal antibody to a cryptic epitope on amyloid fibrils for AL amyloid imaging and therapy, as well as the development of anti-AA amyloid-specific monoclonal antibodies.
Wagner M. Zago Involvement in Phase I/II Studies
Wagner M. Zago has been involved in pioneering clinical studies, including the first-in-human Phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. This study aimed to evaluate the safety and efficacy of NEOD001, an amyloid-directed monoclonal antibody, marking a significant step in therapeutic research for amyloidosis.